SMA patients have at least one copy but possibly multiple copies of the SMN2 gene, so the main challenge for the screening of the SMN1 exon 7 deletion is to avoid false negatives due to the cross-reaction with the SMN2 gene. Here, SMN2 is linked to proximal spinal muscular atrophy.